Abstract
Myc family genes are often deregulated in embryonal tumors of childhood including medulloblastoma and neuroblastoma and are frequently associated with aggressive, poorly differentiated tumors. The Myc protein is a transcription factor that regulates a variety of cellular processes including cell growth and proliferation, cell cycle progression, differentiation, apoptosis, and cell motility. Potential strategies that either inhibit the proliferation-promoting effect of Myc and/or activate its pro-apoptotic function are presently being explored. In this review, we will give an overview of Myc activation in embryonal tumors and discuss current strategies aimed at targeting Myc for cancer treatment.
Keywords: Cancer, child, brain tumor, neuroblastoma, targeted therapies, Myc
Current Cancer Drug Targets
Title: Targeting Myc in Pediatric Malignancies of the Central and Peripheral Nervous System
Volume: 9 Issue: 2
Author(s): Michael A. Grotzer, Deborah Castelletti, Giulio Fiaschetti, Tarek Shalaby and Alexandre Arcaro
Affiliation:
Keywords: Cancer, child, brain tumor, neuroblastoma, targeted therapies, Myc
Abstract: Myc family genes are often deregulated in embryonal tumors of childhood including medulloblastoma and neuroblastoma and are frequently associated with aggressive, poorly differentiated tumors. The Myc protein is a transcription factor that regulates a variety of cellular processes including cell growth and proliferation, cell cycle progression, differentiation, apoptosis, and cell motility. Potential strategies that either inhibit the proliferation-promoting effect of Myc and/or activate its pro-apoptotic function are presently being explored. In this review, we will give an overview of Myc activation in embryonal tumors and discuss current strategies aimed at targeting Myc for cancer treatment.
Export Options
About this article
Cite this article as:
Grotzer A. Michael, Castelletti Deborah, Fiaschetti Giulio, Shalaby Tarek and Arcaro Alexandre, Targeting Myc in Pediatric Malignancies of the Central and Peripheral Nervous System, Current Cancer Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/156800909787580962
DOI https://dx.doi.org/10.2174/156800909787580962 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Anti-inflammatory Compounds as Drug Candidates in Alzheimer’s Disease
Current Medicinal Chemistry Neuroimmune Aspects of Sjogren`s Syndrome: Role of VIP/VPAC System in Immune and Salivary Gland Epithelial Cell Function
Current Pharmaceutical Design Ceramide in Chemotherapy of Tumors
Recent Patents on Anti-Cancer Drug Discovery Exploring Pharmacological Significance of Chalcone Scaffold: A Review
Current Medicinal Chemistry Cytotoxic Effect of the Red Beetroot (Beta vulgaris L.) Extract Compared to Doxorubicin (Adriamycin) in the Human Prostate (PC-3) and Breast (MCF-7) Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Recent Approaches to Novel Anti-Alzheimer Therapy
Current Pharmaceutical Design Substance P and Alzheimer’s Disease: Emerging Novel Roles
Current Alzheimer Research Sera/Organ Lysates of Selected Animals Living in Polluted Environments Exhibit Cytotoxicity against Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Conference Report: The Myriad Pathways of Neurodegeneration Discussed at NEUROCON 2015
Current Aging Science The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
Current Pharmaceutical Biotechnology Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
Current Cancer Drug Targets The Role of β-Amyloid Protein in Synaptic Function: Implications for Alzheimers Disease Therapy
Current Neuropharmacology Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases
Current Drug Targets Transcriptionally Targeted Adenovirus Vectors
Current Gene Therapy Anticancer and Antimicrobial Evaluations on Alternative Reading Frame (ARF) Peptides and their Derivatives
Protein & Peptide Letters Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy The Renin-Angiotensin System and Advanced Glycation End-Products in Diabetic Retinopathy: Impacts and Synergies.
Current Clinical Pharmacology <i>In Vitro</i> Cytotoxicity and Apoptosis Inducing Evaluation of Novel Halogenated Isatin Derivatives
Anti-Cancer Agents in Medicinal Chemistry Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology